My cardiologist just high-fived me at my checkup lol — my results so far

TrialTracker_MD said:

I want to bring up the cardiovascular angle on cardiovascular risk.

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. The "earlier than weight loss explains" argument is weaker than this thread makes it sound. Blood pressure and inflammatory markers move fast and are downstream of early weight loss, so the mechanism is not as cleanly separable as the summaries imply.

DanielChem_CHI said:

My reason for being on this is cardiovascular rather than cosmetic, which puts me in a small minority in most of these threads.

Lp(a) and cardiovascular risk: a nuance that matters. Unlike most lipid markers, Lp(a) is 90%+ genetically determined and doesn't really change with weight loss or GLP-1 therapy.

My Lp(a) has remained at 57 nmol/L across all time points. If yours is elevated (>50 nmol/L), you need additional risk mitigation strategies regardless of your GLP-1 response. Don't assume your medication is covering all cardiovascular risk factors.

Dr.PainCLE said:

The "earlier than weight loss explains" argument is weaker than this thread makes it sound.

Senior perspective on cardiovascular risk: I'm 69 years old and started this journey skeptically. My geriatrician recommended it after years of failed interventions.

13 months later: down 47 lbs, more mobile, pain reduced, medications simplified. My quality of life has improved dramatically. I wish this existed 20 years ago.

To other older adults hesitating: the SELECT trial proved benefit in our age group. You deserve to feel good in your body regardless of age.

A narrower follow-up, since the general answer is now clear:

How long did you give it before you decided it was working?

Dr.RaviCardio said:

Senior perspective on cardiovascular risk: I'm 69 years old and started this journey skeptically.

NNT calculation for cardiovascular risk clinical endpoints: NNT = 1/ARR (absolute risk reduction).

From SELECT trial: MACE at 39 months — 6.5% semaglutide vs 8.0% placebo. ARR = 1.5%. NNT = 67 over 3.3 years.

Compare to established therapies:

These NNTs are clinically meaningful and comparable to accepted cardiovascular interventions.